Since President Donald Trump took office in January and replaced former FTC Chair Lina Khan with Andrew Ferguson, the U.S.

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...